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A number of rare copy number variants (CNVs), including both
deletions and duplications, have been associated with develop-
mental disorders, including schizophrenia, autism, intellectual
disability, and epilepsy. Pathogenicity may derive from dosage
sensitivity of one or more genes contained within the CNV locus.
To understand pathophysiology, the specific disease-causing gene(s)
within each CNV need to be identified. In the present study, we
test the hypothesis that ohnologs (genes retained after ancestral
whole-genome duplication events, which are frequently dosage
sensitive) are overrepresented in pathogenic CNVs. We selected
three sets of genes implicated in copy number pathogenicity: (i)
genes mapping within rare disease-associated CNVs, (ii) genes
within de novo CNVs under negative genetic selection, and (iii)
genes identified by clinical array comparative genome hybridiza-
tion studies as potentially pathogenic. We compared the propor-
tion of ohnologs between these gene sets and control genes,
mapping to CNVs not known to be disease associated. We found
that ohnologs are significantly overrepresented in genes mapping
to pathogenic CNVs, irrespective of how CNVs were identified,
with over 90% containing an ohnolog, compared with control
CNVs >100 kb, where only about 30% contained an ohnolog. In
some CNVs, such as del15p11.2 (CYFIP1) and dup/del16p13.11
(NDE1), the most plausible prior candidate gene was also an ohno-
log, as were the genes VIPR2 and NRXN1, each found in short CNVs
containing no other genes. Our results support the hypothesis
that ohnologs represent critical dosage-sensitive elements of the
genome, possibly responsible for some of the deleterious pheno-
types observed for pathogenic CNVs and as such are readily iden-
tifiable candidate genes for further study.
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Copy number variants (CNVs) are microdeletions or micro-duplications of segments of the genome, ranging from a few
hundred base pairs to several megabases (1). CNVs include
common polymorphic variants segregating in the population and
rare mutations which can either be inherited or occur de novo. In
human disease, the discovery and ability to characterize CNVs
has expanded the range of known pathogenic genome variants,
especially for common, complex neurodevelopmental disorders—
autism spectrum disorders (ASD), intellectual disability, schizo-
phrenia, epilepsy, attention deficit hyperactivity disorder (ADHD),
and speech and language delay (2–6).
Deleterious mutations causing neurodevelopmental disorders
are under strong negative genetic selection pressure (7). The
majority of pathogenic CNV mutations are heterozygous dele-
tions or single-copy duplications, i.e., increase or decrease gene
dosage, and can be considered distinct from pathogenic loss of
function mutations, which are not dosage effects but complete
loss of function. For example, there are recessive homozygous
deletions, such as nephronophthisis, in which gene deletion may
be benign in heterozygous form but deleterious when homozy-
gous (8). There are also allelic series, such as NRXN1 (neurexin 1)
gene deletions, where a heterozygous deletion is a risk factor for
neurodevelopmental disorders (9) and homozygous deletion
causes Pitt–Hopkins-like syndrome (Online Mendelian Inheritance
in Man database, www.omim.org), a severe, syndromic form of
neurodisability (10). They also tend to be pleiotropic, i.e., show
association across neurodevelopmental phenotypes, and also have
non-CNS phenotypes, including obesity and cardiac anomalies (11).
It is possible that genomic deletions are more likely to cause
dosage sensitivity compared with duplications because the fold
change is greater for deletions, i.e., there is a bigger proportional
effect on dosage. There is evidence for this from nonallelic ho-
mologous recombination-mediated CNVs, such as 15q11.2 and
15q13.3, where the reciprocal mutational event should generate
an equal number of deletions and duplications. The 15q11.2
duplication appears to have a benign or at least milder pheno-
type compared with the reciprocal deletion, and the population
frequency of the duplication (0.39%) is greater than the deletion
(0.18%), indicating the latter is under stronger negative genetic
selection (5). On the other hand, overexpression in some de-
velopmental systems could have a bigger phenotypic effect than
reduction in expression, and in some cases, both deletion and
duplication are pathogenic, such as distal 16p11.2 (12).
Pathogenic CNVs provide an opportunity for stratified medi-
cine, because as high or moderate risk factors they may allow the
selection of patients for specific interventions, such as targeted
pharmacotherapy, and they may clarify disease pathophysiology
and the relationship between different diagnostic categories.
However, it is not straightforward to identify the specific genes
that give rise to the observed phenotypes. Thus, although a few
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pathogenic CNVs can be mapped to a single gene, such asNRXN1
or VIPR2 (vasoactive intestinal peptide receptor 2), providing a
direct route to the pathophysiology of disease, most pathogenic
CNVs are large, covering several megabases, and typically delete
or duplicate multiple genes (13, 14).
Phenotypes are also complex. For example, 22q11.2 deletion
syndrome consists of variable combinations of over 190 pheno-
typic characteristics, including conotruncal heart and cleft palate
defects in about 70% of cases (15). Identifying the deleted genes
involved in neurodevelopmental phenotypes such as psychosis
has proven difficult as there are a number of plausible candidates
involved in neurotransmission, neuronal development, myelina-
tion, microRNA processing, and posttranslational protein mod-
ifications (16), including catechol-(O)-methyl transferase (17)
and proline dehydrogenase (18).
Various strategies are possible to try and understand the re-
lationship between specific genes and phenotypes within patho-
genic CNVs. These include deletion mapping, i.e., searching for
critical disease-associated intervals within larger CNV bound-
aries to narrow the number of genes involved; searching for in-
activating mutations in single genes which carry the same
phenotype as the pathogenic CNV (19); the use of bioinformatic
information such as gene function and known disease associa-
tions; and the analysis of deleterious mouse knockout pheno-
types to identify the most likely candidate gene(s) for a given
CNV phenotype (20). Here we explore a unique evolutionary
approach that identifies genes within pathogenic CNVs that have
patterns of gene duplication characteristic of dosage-balanced
genes (21).
Dosage balance may exist between two or more genes due to
stoichiometric constraints of the protein complexes or the bio-
chemical pathways in which the gene products participate (22,
23). Changes in gene copy number through gene duplication or
loss lead to increases or decreases of gene product in the cell (24,
25). In the case of dosage-balanced genes such changes are
deleterious and are removed by natural selection. Thus, a gen-
eral feature of dosage-balanced genes is their low duplicability
(26). An exception to this is duplication through whole-genome
duplication (WGD) which increases all genes equally, main-
taining the relative frequencies. Thus, WGD creates a unique
opportunity for the duplication of dosage-balanced genes be-
cause it guarantees the simultaneous duplication of all compo-
nents of a balanced set (26–28). Furthermore, once the genes
have been duplicated, subsequent loss of individual genes would
result in a dosage imbalance, thus leading to biased retention of
dosage-balanced genes.
Two WGD events occurred early in the vertebrate lineage,
generating initially tetraploid genomes. The genome duplication
events were followed by extensive chromosomal rearrangement
and loss of many duplicate copies (29–32). The 20–30% of the
protein-coding genes in the human genome that can be traced
back to these events (21, 32) have been postulated to have ac-
celerated the evolution of vertebrate complexity, as they are
enriched for developmental genes (33–35) and members of pro-
tein complexes (36).
Duplicated genes derived from WGD are known as “ohno-
logs” (37). Consistent with expectations, ohnologs have many
characteristics of dosage-balanced genes. Mammalian ohnologs
are more essential (i.e., knockout of one copy is more likely to
result in sterility or inviability) than paralogs generated by small-
scale duplication (SSD) and have comparable essentiality to
singleton genes (36), i.e., copy number change is under negative
selection. The overrepresentation of ohnologs in protein com-
plexes is also consistent with the gene dosage balance hypothesis,
which states that the stoichiometry of members of multisubunit
complexes affects the function of the whole because of the ki-
netics and mode of assembly. Changing the dosage of a struc-
tural gene (for example by deletion or duplication) changes its
expression in proportion to copy number (28, 38). If the product
of a gene that changes in copy number belongs to a large protein
complex, this may generate stoichiometric imbalance among
members of the complex, resulting in a deleterious dominant
negative phenotype. Finally, ohnologs were observed to be re-
sistant to fluctuations in relative quantities by SSD and the CNV
(21, 39), and, consistent with this, they are strongly associated
with disease. In particular, Down syndrome caused by trisomy 21
appears to be caused in large part by the deleterious effects of the
1.5-fold increase in dosage of ohnologs on that chromosome (21).
In the present study we created three lists of genes from
known or potentially pathogenic CNVs, and tested these for
inclusion of ohnologs. These comprised CNVs associated with
schizophrenia and other neurodevelopmental disorders, de novo
CNVs under negative genetic selection identified in an Icelandic
sample, which are possibly associated with disorders causing
reduced fecundity (5), and CNVs from a comprehensive CNV
morbidity map of neurodevelopmental delay (40). The pro-
portion of ohnologs in these pathogenic CNV sets was compared
with control copy number polymorphisms of a similar size range,
which should not be under negative genetic selection, identified
in the general population from two studies (41, 42). In addition,
we tested whether the ohnologs mapping to pathogenic CNVs
were more likely to encode proteins from multisubunit com-
plexes, or showed enrichment for biological pathways, being thus
more likely to represent dosage-balanced genes.
Results
Table 1 shows the list of CNVs associated with complex neu-
rodevelopmental disorders (schizophrenia, autism, intellectual
disability, neurodevelopmental delay, seizures, and epilepsy) that
were used in the analysis. We included a total of 15 CNVs, with
interval sizes ranging from 140 kb to 6.8 megabases (Mb). These
covered total genome regions of 21.1 Mb containing 208 genes
(minimal regions) and 37.9 Mb containing 369 genes (maximal
regions). The list of CNVs is not exhaustive but includes CNVs
with previous evidence of disease association from individual
studies largely overlapping with a list of pathogenic CNVs pro-
posed by Kirov et al. (43). In addition, we analyzed 440 genes
that mapped to the Icelandic de novo CNV gene list (5), and
1,137 genes from the CNVs in the morbidity map list (40) (in-
cluding additional genes not listed in the Cooper et al. paper, but
which map within the CNV intervals).
Examination of these genes lists, plus the set of Icelandic
CNVs under negative genetic selection (5) and morbidity map
gene list (40), produced a list of 63 ohnolog genes which mapped
to minimal CNV intervals, 93 ohnologs in the broad CNV
intervals, 127 ohnologs in the Icelandic de novo CNV gene list,
and 359 ohnologs from the morbidity map list (Table 2). Tables
S1 and S2 show the list of genes and the ohnologs mapping to the
narrow and broad intervals for the 15 established pathogenic
CNV loci analyzed, and Tables S3 and S4 show the ohnologs
mapping to the Icelandic de novo and the morbidity map lists,
respectively.
More than 90% of the CNVs from the three pathogenic sets of
genes contained an ohnolog, which is much greater than in the
control CNV set, where about 30–48% of CNVs contained an
ohnolog (Table 2). However, control CNVs were significantly
smaller than pathogenic CNVs and thus less likely to contain an
ohnolog because of encompassing fewer genes. To correct for
CNV size, in the statistical analysis we also tested the proportion
of genes that were ohnologs in each set of CNVs. We found
a significant enrichment of ohnologs in all groups of pathogenic
CNVs examined, with 63 of 208 (30%) in the narrow group of
pathogenic CNVs, 127 of 440 (29%) in the Icelandic de novo
CNVs, and 359 of 1,137 (32%) in the morbidity map set. The
lowest proportion of ohnologs was observed in the broad defi-
nition of pathogenic CNVs (91 of 369, 25%), as expected. The
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density of ohnologs among genes mapping to pathogenic CNVs
was significantly higher than that observed in the Wellcome
Trust Case Control Consortium (WTCCC) control set (26 of
232; Table S5) or in the Conrad discovery set >100 kb (125 of
775; Table S6). These differences were highly statistically sig-
nificant (Table 3). However, the ohnolog density in the Conrad
HapMap control set (80 of 336; Table S7) was similar to the one
observed in the broad group of pathogenic CNVs.
Because we previously showed that dosage-balanced ohnologs
are significantly enriched in protein complex members, de-
velopmental genes, and transcription factors (21), we tested this
finding in our list of CNVs associated with neurodevelopmental
disorders (Table 1), and observed that a larger proportion of
ohnologs mapping to these CNVs were members of protein
complexes compared with ohnologs within control CNVs (20.9%
vs. 10.4%), but this difference was not statistically significant (χ2
test). Finally, we performed Gene Ontology (GO) analysis on the
same set of pathogenic CNVs (Table 1) but we found no sig-
nificant association with any biological process for ohnologs
mapping to these CNVs.
Discussion
In the present study, we found that ohnologs were overrepre-
sented in all three sets of genes mapping to pathogenic CNVs,
with over 90% containing an ohnolog compared with about 30%
of control CNVs over 100 kb in size, and the density of ohnologs
was also higher. We also found that ohnologs in pathogenic CNVs
are more frequently members of protein complexes, although this
was not statistically significant. Our findings support the hypoth-
esis that pathogenicity may derive from dosage sensitivity of one
or more genes contained within the CNV locus.
Although we attempted to match CNVs for size, in our case
CNVs were larger in size than our control CNVs. The reason
control CNVs are smaller is likely to relate to the increased
likelihood of larger CNVs being pathogenic (3, 12, 40). There-
fore, for the statistical analysis we tested the proportion of genes
that are ohnologs in each set of CNVs to control for CNV size,
and this should be regarded as the main statistic of the analysis.
A limitation of the study is the differential CNV detection sen-
sitivities of the genotyping methods (platforms and algorithms)
used in different studies. Because our aim was not the direct
comparison of the frequency of CNVs between cases and con-
trols, but the identification of nonexhaustive lists of pathogenic
and nonpathogenic CNVs, we were able to overcome this problem
by making some assumptions: (i) irrespective of the method used
for the studies identifying pathogenic CNVs, we accepted the
findings when the same genotyping method was used in both
cases and controls. The inclusion of false-positives probably
reduces the power of our analysis and does not abate our find-
ings that pathogenic CNVs contain more ohnologs. (ii) The
nonpathogenic CNVs were identified through CNV discovery
methods, which preserve a low false-positive rate. For our anal-
ysis the specificity of the control CNV list was more important
than the sensitivity, as we do not require exhaustive but validated
lists of control CNVs.
Table 1. Chromosomal bands and genome coordinates of the CNVs associated with schizophrenia and neurodevelopmental disorders
Locus CNV region Hg19 coordinates N Gene boundaries Oh Size (kb) Associated disorders Refs
1q21.1 del Min 146,6-147,6 12 PRKAB2-NBPF24 4 1,050 Sz, ID, Epil, ASD 4, 5, 52, 53, 55
Max 146,5-148,7 20 PRKAB2- LOC645166 4 2,220
2p16.3 del Min 49,8-51,4 1 NRXN1 1 1,600 Sz, ID, Epil, ASD 3, 9, 52, 55, 56
Max 49,8-51,4 1 NRXN1 1 1,600
3q29 del Min 195,8-197,3 21 TFRC-BDH1 8 1,540 Sz, ID, ASD 55, 57, 58
Max 195,8-197,3 21 TFRC-BDH1 8 1,540
7q11.23 dup Min 72,4-74,2 37 NSUN5P2-GTF2I 9 1,770 Sz, ASD 59, 60
Max 72,4-74,2 37 NSUN5P2-GTF2I 9 1,770
7q36.1 del Min 145,3-148,1 1 CNTNAP2 1 2,860 Sz, ID 56, 61
Max 145,3-148,1 1 CNTNAP2 1 2,860
7q36.3 dup Min 158,8-159,0 1 VIPR2 1 140 Sz 54, 55
Max 157,3-159,0 7 PTPRN2-VIPR2 3 1,649
10q11.22-23 dup Min 49,3-51,6 28 FRMPD2-TIMM23 6 2,300 DD 62
Max 46,8-52,4 60 FAM35BP-SGMS1 15 5,600
15q11.2 del Min 22,7-23,2 5 TUBGCP5-WHAMMP3 2 500 Sz, ID, ASD 5, 52, 63
Max 22,7-23,2 5 TUBGCP5-WHAMMP3 2 500
15q11-q13 dup Min 23,8-28,6 14 MIR4508-HERC2 6 4,770 ASD 64
Max 22,4-29,1 34 OR4M2- LOC100289656 8 6,709
15q13.3 del Min 32,3-32,5 1 CHRNA7 0 160 Sz, ID, Epil. 5, 6, 49, 52, 53, 55,
63, 65, 66Max 29,2-33,0 28 APBA2-SCG5 6 3,793
16p13.11 dup/del Min 15,5-16,3 9 MPV17L-ABCC6 4 850 Sz, ID, ASD, ADHD 46, 52, 63, 67
Max 14,9-18,6 26 NOMO1-NOMO2 5 3,671
16p11.2 dup Min 29,7-30,1 27 SPN-GDPD3 9 452 Sz, ID, Epil., ASD,
ADHD, BD
12, 55, 64, 68-70
Max 29,6-30,2 32 SLC7A5P1-CORO1A 12 610
16p12.1 del Min 21,9-22,4 8 UQCRC2-CDR2 1 440 DD, Epil. 63, 64, 71
Max 21,8-22,4 13 RRN3P1-CDR2 2 600
17q12 del Min 34,8-36,1 15 ZNHIT3-HNF1B 5 1,290 Sz, HNPP, DD 72, 73
Max 34,4-36,1 24 CCL18-HNF1B 5 1,750
22q11 del Min 18,9-20,3 28 DGCR6-RTN4R 6 1,400 Sz, ID, ASD, ADHD,
OCD, Mood
52, 53, 55, 64
Max 18,9-21,8 65 DGCR6- RIMBP3C 12 2,900
Minimal CNV region is defined as the smallest size typically associated, which should approximate to the “critical” deletion or duplication sufficient to
cause the disease phenotype and maximal CNV region as the largest extent of deletion or duplication typically seen at the locus. ADHD, attention deficit
hyperactivity disorder; ASD, autism spectrum disorder; BD, bipolar disorder; DD, developmental delay; Epil, epilepsy; HNPP, hereditary neuropathic pressure
palsies; ID, intellectual disability; Mood, mood disorders (including depression); N, number of genes; OCD, obsessive compulsive disorder; Oh, number of
ohnologs; Sz, schizophrenia.
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Our results are important for two reasons. First, from an
evolutionary genetic perspective, they confirm the previous ob-
servation that ohnologs are more likely to be refractory to copy
number change and represent a class of dosage sensitive genes.
Second, from a clinical genetic perspective, they provide a tool
to help determine which gene(s) from within a pathogenic CNV
are more likely to be causative for the deleterious phenotypes
observed at that locus. The ability to identify these is important
for understanding the pathophysiology of neurodevelopmental
disorders, necessary for the development of new treatments and
preventative measures.
However, analysis of ohnologs alone will not provide sufficient
information to determine which gene(s) within a CNV interval
are pathogenic; not all ohnologs are dosage sensitive and many
dosage-sensitive genes will not be ohnologs. It is interesting to
consider the possibility that the pathogenicity of some CNVs may
be due to the combined effect of several mildly dosage-sensitive
genes which perhaps are not sufficiently dosage sensitive to show
a phenotype when duplicated or deleted individually. Alterna-
tively there may be a digenic phenomenon. One of these is likely
to occur in 22q11.2 deletion syndrome, where there are many
ohnologs, and a number of genes involved in neurotransmission,
neuronal development, myelination, microRNA processing, and
posttranslational protein modifications which could plausibly
contribute to the neurobehavioral phenotypes (16). Most of the
CNVs we examined contain multiple ohnologs, such as 16p13.11,
with four ohnologs from nine genes in the critical region (Fig. S1).
One ohnolog, MYH11, is thought to carry the risk of developing
aortic dissection in patients with 16p13.11 duplications (44),
whereas NDE1, also an ohnolog, is the strongest candidate for
neurodevelopmental phenotypes associated with CNVs at this
locus (45, 46). Two other ohnologs within the critical region,
ABCC1 and ABCC6, encode the multidrug resistance-associated
proteins 1 and 6.
If we examine single genes that are pathogenic when deleted
(CHRNA7, VIPR2, CNTNAP2, and NRXN1) (Table 1), three are
ohnologs and one (CHRNA7) is not. CHRNA7 is part of a larger
family of 17 closely related mammalian ligand-gated ion channel
genes that arose from SSD events (47). Their gene products form
stochastic multiprotein complexes which can be heteromeric or
homomeric; in their case, changes in gene dosage may affect the
stoichiometry and thus function of these ion channels in the cell.
In addition there is a human-specific chimeric gene to CHRNA7
(CHRFAM7A), a partial duplication which arose through seg-
mental duplication. The presence of CHRFAM7A could also
contribute to CHRNA7 dosage sensitivity, as it may be a domi-
nant negative regulator of α7nAChR function (48).
The ohnolog gene list we have is unlikely to be perfect—there
are likely to be false negatives (failure to identify a true ohnolog)
and false positives (some genes identified may not in fact be
ohnologs)—but we are confident that the errors are minimized.
The fact that a gene is an ohnolog is not sufficient to determine
that a particular gene within a genome imbalance locus is the
source of deleterious phenotypes. Additional strategies are needed
for the mapping of pathogenicity, including deletion mapping, i.e.,
searching for the smallest disease associated intervals within larger
CNV boundaries to narrow the number of candidate genes in-
volved, and screening for mutations within individual genes (19, 49).
In this regard, we observed that the proportion of ohnologs in
our own definition of minimal regions at CNV loci is greater
than in the broadly defined region. However, this difference was
not statistically significant, and indeed for some CNV loci (for
example 10q11.22-23) the proportion of ohnologs increased in
the larger CNV. For the critical regions definition, we simply
took the smallest region consistently deleted or duplicated;
however, deeper phenotyping combined with case-control pop-
ulation association analysis will be needed to properly define
critical CNV regions for specific phenotypes. Furthermore, as we
know from analysis of NRXN1, where nonpathogenic intronic
deletions are seen within disease population (9), pathogenic
CNV loci may harbor nonpathogenic CNVs that could confound
deletion-mapping studies.
In conclusion, we found that ohnologs are enriched in path-
ogenic CNVs, tend to map to multiprotein complexes, and that
specific ohnolog genes within the interval have a plausible
Table 2. Number and density of ohnologs within each class of CNV, and proportion of genes within CNVs which are ohnologs
Cooper
Pathogenic
(narrow)
Pathogenic
(broad)
Iceland
(de novo)
WTCCC
controls
Conrad >100
kb
Conrad
HapMap
CNVs (containing
genes)
51 15 15 22 66 194 88
CNVs with an ohnolog 47 14 15 20 20 69 42
Ohnologs/CNV* 0.92 0.93 1.00 0.91 0.30 0.36 0.48
No. of genes 1,137 208 369 440 232 775 336
No. of ohnologs 359 63 91 127 26 125 80
Ohnolog/gene† 0.32 0.30 0.25 0.29 0.11 0.16 0.24
CNV total size (Mb)‡ 100 21 38 44 19 65 33
Genes/1 Mb (CNV size){ 11.35 9.81 9.87 10.00 12.25 11.84 10.32
Ohnologs/1 Mb
(CNV size){
3.58 2.97 2.45 2.89 1.37 1.91 2.46
*Ohnolog/CNV is the proportion of CNVs containing at least one ohnolog.
†Ohnolog/gene is the density of ohnologs within a CNV, i.e., the number of ohnologs divided by the total number of known genes within the CNV intervals.
‡CNV total size is the total size of CNVs included in each list.
{These last two rows in the table are the density of genes and ohnologs, respectively.
Table 3. Comparison of ohnolog presence and ohnolog density
in pathogenic and control CNVs (Fisher’s exact test P values)
Cooper
Pathogenic
(narrow)
Iceland
(de novo)
Ohnolog/CNV*
WTCCC controls 5.89E-12 8.26E-06 6.24E-07
Conrad >100 kb 9.98E-14 1.19E-05 4.98E-07
Conrad HapMap 4.62E-08 0.001 2.08E-04
Ohnolog/gene†
WTCCC controls 2.55E-11 7.78E-07 8.09E-08
Conrad >100 kb 8.73E-15 1.04E-05 2.26E-07
Conrad HapMap 0.007 0.11 0.12
*The number of ohnologs per CNV.
†The density of ohnologs within a CNV, i.e., the number of ohnologs divided
by the total number of known genes within the CNV intervals.
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connection with the observed phenotypes. This supports the
hypothesis that these genes are critical dosage-sensitive ele-
ments of the genome and may be responsible for some of the
deleterious phenotypes observed for pathogenic CNVs. This
observation will also provide another tool to help determine the
pathogenic gene(s) from within CNV intervals, although the ul-
timate certainty will be from identifying inactivating mutations in
single genes within the interval that carry the same phenotype
as the pathogenic CNVs (19).
Materials and Methods
Genes Mapping to Pathogenic CNVs. Three lists of pathogenic or potentially
pathogenic CNVs were prepared. The first included a list of CNVs associated
with schizophrenia and other neurodevelopmental disorders (Table 1). This
was composed from published case-control studies that identified CNVs as-
sociated with schizophrenia, autism, neurodevelopmental delay, seizures,
and intellectual disability. It is not an exhaustive list, and does not include
many rare CNVs associated with severe or syndromic disorders. For each CNV
we extracted the coordinates of the endpoints as defined by CNVs from the
literature and from the Brain and Body Genetic Resource Exchange genome
imbalance database (http://bbgre-dev.iop.kcl.ac.uk) or Database of Chro-
mosomal Imbalance and Phenotype in Humans Using Ensembl Resources
(http://decipher.sanger.ac.uk), which contain multiple incidences of patho-
genic CNVs. These loci were defined by gene boundaries (inclusive distal and
proximal gene) and then converted to HG19 (NCBI37/hg19). The genome-
wide screen for CNVs in most disease-association studies was performed with
SNP arrays usually validated by array comparative genomic hybridization
(CGH). The CNV breakpoint accuracy depends on the platform used and the
CNV detection algorithm. In general SNP arrays tend to underestimate the
size of CNVs but high-resolution platforms are highly consistent in the as-
signment of start and end coordinates (50).
Because CNVs at individual loci can vary in size, wemade two definitions at
each locus, a minimal CNV region (the smallest size typically associated, which
should approximate to the critical deletion or duplication sufficient to cause
the disease phenotype) and a maximal CNV region (the largest extent of
deletion or duplication typically seen at the locus). For example, because case-
control association indicates that the pathogenic CNVs at 16p13.11 always
include interval II (chr16: 15,380,000–16,230,000), we defined this as the
critical region, whereas the maximal CNV locus was defined as including the
broadest regions I, II, and III (chr16: 14,828,500–18,500,000). For the 22q11.2
deletion (velocardiofacial syndrome/DiGeorge syndrome) there are two
typical-sized CNVs, 1.5 and 3 Mb (51). We defined the minimal CNV region
(corresponding to the 1.5-Mb deletion), as the region chr22: 18,870,000–
20,270,000 (1.4 Mb) containing the genes DGCR6 (uc002zoh.2) at the prox-
imal end and RTN4R (uc002zru.1) at the distal end, whereas the maximal
CNV region chr22: 18,870,000–21,770,000 (2.9 Mb) (corresponding to the
3-Mb deletion), was defined referring to the size of the broadest 22q11.2
deletions identified by Kirov et al. (52) and by the International Schizo-
phrenia Consortium (53), and included the genes DGCR6 (uc002zoh.2) at the
proximal end and RIMBP3B (uc002zuq.2) at the distal end. This method was
used to test the hypothesis that minimal or critical regions of pathogenic
CNVs would show enrichment over maximal regions, however, some CNV
loci also contained nonoverlapping deletions and duplications, such as those
in NRXN1 (2p16.3) (9, 52) and VIPR2 (7q36.3) (54, 55). All definitions of CNV
boundaries were performed blind to the identification of ohnologs in
the region.
The second list consisted of 66 de novo CNVs identified in an Icelandic
sample of trios and parent–offspring pairs (9,878 transmissions) enriched for
those regions that mutate most often. These CNVs under negative selection
pressure may confer risk of disorders that reduce the fecundity of affected
individuals (5). The third list was taken from a large study presenting a CNV
morbidity map of developmental delay (40).
Genes Mapping to Control CNVs. To test for enrichment of ohnologs in
pathogenic CNVs we compared genes in these regions with genes in CNVs
identified in control populations without disease. Nonpathogenic CNVs were
taken from two studies by the Wellcome Trust CNV Project (www.sanger.ac.
uk/research/areas/humangenetics/cnv/). The study by Conrad et al. (42) used
a CNV discovery sample which comprised 20 HapMap (http://hapmap.ncbi.
nlm.nih.gov/) individuals of European and 20 of West African ancestry. CNVs
were identified with CGH using a set of 20 NimbleGen arrays with stringent
calling criteria. In collaboration with the WTCCC, a CNV-typing array was
designed which comprised 105,000 long oligonucleotide probes targeted to
∼11,000 candidate CNV loci. This array was used to genotype 450 HapMap
samples (180 CEU [Utah Residents (CEPH) with Northern and Western Eu-
ropean ancestry], 180 YRI [Yoruba in Ibadan, Nigeria], 45 JPT [Japanese in
Tokyo, Japan], and 45 CHB [Han Chinese in Bejing, China]) in this study, and
∼19,000 individuals (including 3,000 controls) in a parallel study by the
WTCCC (41). Validated CNVs larger than 100 kb from the discovery experi-
ment and the two additional control samples (450 HapMap and 3,000
WTCCC controls) were used as three separate reference lists for our study.
Ohnologs. A total of 7,294 human ohnolog genes (duplicated genes derived
from WGD) were defined as described in Makino and McLysaght (21).
Ohnologs are genes duplicated at the base of the vertebrate tree and lo-
cated on paralogous chromosomal regions.
Protein Complexes and GO. We obtained a list of members of human protein
complex from the Human Protein Reference Database (HPRD) Release 9
(www.hprd.org). GO slim annotation for biological processes of human
was downloaded from ftp://ftp.geneontology.org/pub/go/GO_slims. We ex-
cluded the GO ID no. GO:0008150 (biological process unknown). The number
of each GO term assigned into ohnologs in pathogenic CNVs was counted.
We calculated the P value for each GO term by comparison of the number of
observed GO term with that of expected GO term based on hypergeometric
distribution using all genes. The estimated P values were adjusted by Bon-
ferroni correction.
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